255 related articles for article (PubMed ID: 21618503)
1. Cancer immunotherapy: Progress and challenges in the clinical setting.
Zarour HM; Ferrone S
Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503
[No Abstract] [Full Text] [Related]
2. Cocktails for cancer with a measure of immunotherapy.
Ledford H
Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078
[No Abstract] [Full Text] [Related]
3. Breakthrough of the year 2013. Cancer immunotherapy.
Couzin-Frankel J
Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
[No Abstract] [Full Text] [Related]
4. The struggle to do no harm in clinical trials.
Schmidt C
Nature; 2017 Dec; 552(7685):S74-S75. PubMed ID: 29293235
[No Abstract] [Full Text] [Related]
5. Cancer immunotherapy.
Bender E
Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244
[No Abstract] [Full Text] [Related]
6. Cancer Immunotherapy: Theory and Application.
Chen G; Bodogai M; Tamehiro N; Shen C; Dou J
J Immunol Res; 2018; 2018():7502161. PubMed ID: 30035133
[No Abstract] [Full Text] [Related]
7. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
Tran E; Robbins PF; Rosenberg SA
Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
9. Tumor immunology top 10 list.
Finn OJ
Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
[No Abstract] [Full Text] [Related]
10. Do no harm.
Nat Biotechnol; 2013 May; 31(5):365. PubMed ID: 23657369
[No Abstract] [Full Text] [Related]
11. Future directions in tumor immunotherapy: CTLA4 blockade.
Gulley JL; Dahut WL
Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
[No Abstract] [Full Text] [Related]
12. Human Tumor Antigens and Cancer Immunotherapy.
Vigneron N
Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
[TBL] [Abstract][Full Text] [Related]
13. Neoantigens in the immuno-oncology space.
Arlen PM
Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
[No Abstract] [Full Text] [Related]
14. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
15. Future of immunotherapy drug combinations and biomarkers.
Schmidt C
J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
[No Abstract] [Full Text] [Related]
16. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
17. Future directions in bladder cancer immunotherapy: towards adaptive immunity.
Smith SG; Zaharoff DA
Immunotherapy; 2016; 8(3):351-65. PubMed ID: 26860539
[TBL] [Abstract][Full Text] [Related]
18. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
19. Safety concerns blight promising cancer therapy.
Ledford H
Nature; 2016 Oct; 538(7624):150-151. PubMed ID: 27734893
[No Abstract] [Full Text] [Related]
20. Strategies for combining immunotherapy with radiation for anticancer therapy.
Seyedin SN; Schoenhals JE; Lee DA; Cortez MA; Wang X; Niknam S; Tang C; Hong DS; Naing A; Sharma P; Allison JP; Chang JY; Gomez DR; Heymach JV; Komaki RU; Cooper LJ; Welsh JW
Immunotherapy; 2015; 7(9):967-980. PubMed ID: 26310908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
